SCHEMBL289814

SCHEMBL289814

CCCC[CH]C(O)CC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15846758 0.92 KMT2A (0.41)
SCHEMBL28193263 0.90 TSHR (0.44)
SCHEMBL7948617 0.90 TSHR (0.44)
SCHEMBL5685729 0.90 TSHR (0.44)
SCHEMBL290688 0.86
SCHEMBL2360898 0.84 ACHE (0.42)
SCHEMBL2369749 0.84
SCHEMBL4552804 0.82 TRPA1 (0.50)
SCHEMBL1986858 0.82 SMN1; SMN2 (0.43)
SCHEMBL11517580 0.80 ALDH1A1 (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230054591-A1 AGROCHEMICAL GEL COMPOSITIONS MONSANTO TECHNOLOGY LLC 2023-02-23 US claimed
EP-2427172-B1 A METHOD FOR TREATING OVERACTIVE BLADDERS AND A DEVICE FOR STORAGE AND ADMINISTRATION OF TOPICAL OXYBUTYNIN COMPOSITIONS ALLERGAN SALES LLC (US) 2017-11-01 EP claimed
EP-1565136-B1 COMPOSITIONS FOR TRANSDERMAL OXYBUTYNIN THERAPY WATSON PHARMACEUTICALS INC (US) 2015-02-25 EP claimed
EP-2612629-A1 Compositions for transdermal oxybutynin therapy Watson Pharmaceuticals, Inc. (US) 2013-07-10 EP claimed
EP-2544532-A2 AGROCHEMICAL GEL COMPOSITIONS Monsanto Technology LLC (US) 2013-01-16 EP claimed
US-8241662-B2 Unoccluded topical oxybutynin gel composition and methods for transdermal oxybutynin therapy WATSON LABORATORIES, INC. (US) 2012-08-14 US claimed
WO-2011113061-A2 AGROCHEMICAL GEL COMPOSITIONS MONSANTO TECHNOLOGY LLC (US) 2011-09-15 WO claimed
US-11707451-B2 Pharmaceutical composition for modified release ASTELLAS PHARMA INC. (JP) 2023-07-25 US disclosed
US-20230054591-A1 AGROCHEMICAL GEL COMPOSITIONS MONSANTO TECHNOLOGY LLC 2023-02-23 US disclosed
US-20220280418-A1 ORAL PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2022-09-08 US disclosed
EP-4015001-A1 ORAL PHARMACEUTICAL COMPOSITION Otsuka Pharmaceutical Co., Ltd. (JP) 2022-06-22 EP disclosed
EP-4015002-A1 ORAL PHARMACEUTICAL COMPOSITION CONTAINING HETEROCYCLIC COMPOUND Otsuka Pharmaceutical Co., Ltd. (JP) 2022-06-22 EP disclosed
CN-114286722-A Catalyst comprising coke and process for producing dienes 维尔萨利斯股份公司 2022-04-05 CN disclosed
US-20070148195-A1 Compositions and methods for transdermal oxybutynin therapy ALLERGAN SALES, LLC 2007-06-28 US disclosed
US-7179483-B2 Compositions and methods for transdermal oxybutynin therapy WATSON PHARMACEUTICALS, INC. (US) 2007-02-20 US disclosed
US-7029694-B2 Compositions and methods for transdermal oxybutynin therapy WATSON LABORATORIES, INC. (US) 2006-04-18 US disclosed
US-20050226898-A1 Compositions and methods for transdermal oxybutynin therapy WATSON PHARMACEUTICALS, INC. 2005-10-13 US disclosed
EP-1565136-A2 COMPOSITIONS AND METHODS FOR TRANSDERMAL OXYBUTYNIN THERAPY Watson Pharmaceuticals, Inc. (US) 2005-08-24 EP disclosed
WO-2004041188-A2 COMPOSITIONS AND METHODS FOR TRANSDERMAL OXYBUTYNIN THERAPY WATSON PHARMACEUTICALS, INC. (US) 2004-05-21 WO disclosed
US-20030147926-A1 Compositions and methods for transdermal oxybutynin therapy WATSON PHARMACEUTICALS, INC. 2003-08-07 US disclosed